ACR Best Abstracts - Day 3 Save

The last day was jammed with important reports and research including the late breaking abstracts. 

What imaging modality is best in GCA?

Dutch study: n=42
?GCA got all three of USS, PET/CT, MRI

Overall performance basically the same between all three.

Important details in 🧵
but reasonable to say you can be happy with whatever you’ve got!

ABST1617 #ACR22 #ACRBest @RheumNow pic.twitter.com/HGt0vW9Z38

— David Liew (@drdavidliew) November 13, 2022

HCQ does not prevent RA in CCP+ pts w/out clinical arthritis!

Stop RA: RCT HCQ vs. PBO in pts at-risk

Interim analysis 140+ pts
RA development HCQ 34% vs. PBO 36%

Trial interrupted as met futility criteria.https://t.co/n31OmsjLhM

Abs#1604 #ACR22 @RheumNow #ACRBest pic.twitter.com/NVYS8kB5to

— Aurelie Najm (@AurelieRheumo) November 13, 2022

Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE?
363 pt P2, double-blind PBO-controlled 48 wk study
DEUC 3 mg BID, 6 BID, 12 QB vs PBO:
At 32wk: DEUC 3BID & 6BID > PBO, sustained across all groups at 48wk.
AEs: similar bw PBO and DEUC. No VTE@RheumNow #ACRBest pic.twitter.com/uamJe05odq

— Eric Dein (@ericdeinmd) November 13, 2022

Are your SpA pts planning on conceiving? Be careful with NSAID use
French study found age and NSAID use associated with longer time-to-conception.
Factors not associated: smoking, BASDAI score, DMARD use#ACRBest Abs#1673 @RheumNow #ACR22 pic.twitter.com/D63XTY7IB8

— Robert B Chao, MD (@doctorRBC) November 14, 2022

Get the skinny on Bimmy! Gotta learn this name #Bimekizumab in bio naive PsA N=852 Bimmy=IL17 A & F inhibitor Great data on skin & joints. Where will it fit in as we have other IL17Ai’s is IL17F giving added value? #ACR22 #ACRBest @RheumNow pic.twitter.com/wNAzTaLhsM

— Janet Pope (@Janetbirdope) November 14, 2022

#ACR22 Abstr#2061 It's time to tight control newly diagnosed #lupus nephritis patients. In a cohort study which 16% developed advanced CKD, risk was reduced if remission achieved by 12 mths of diagnosis. =>1 flare & shorter time-on-therapy increased risk @RheumNow #ACRBest pic.twitter.com/swYn2g4hqe

— Md Yuzaiful Md Yusof (@Yuz6Yusof) November 14, 2022

Which patients with IIM are high risk for #cancer?

Abstract #0002 #ACR22 @RheumNow #ACRBest

📍Dermatomyositis
📍Anti-TIF-gamma, anti-NXP2
📍Age > 40y at dz onset
📍Dysphagia
📍Cutaneous necrosis
📍Persistent high dz despite immunosuppressive tx

— Catherine Sims, MD (@DrCassySims) November 14, 2022

Very cool preclinical plenary @MaxKonigMD

Instead of CAR-T to just CD19, created CATCRs that selectively kill specific B cells (beta2 glycoprotein expressing cells)

Early days but super interesting possibilities - APS, SLE, AAV, & more? #ACR22 @rheumnow #ACRBest Abstr#1677 pic.twitter.com/nS3YtR6wN9

— Mike Putman (@EBRheum) November 14, 2022